title: Different domains of glycoprotein 96 influence HPV16 E7 DNA vaccine potency via electroporation mediated delivery in tumor mice model.
abstract: DNA vaccines have emerged as a promising approach for generating antigen-specific immunotherapy. However, due to their low immunogenicity, there is a need to enhance DNA-based vaccine potency. Two main strategies to increase DNA-based vaccine potency are the employment of immuno-adjuvants such as heat shock proteins (HSPs) and a method of improving the delivery of naked plasmid DNA by electroporation. In the current study, we evaluated the effects of linkage of human papillomavirus (HPV) type 16 E7 as a model antigen to N-terminal and C-terminal of glycoprotein 96 (NT-/CT-gp96) on the potency of E7-specific immunity generated by DNA vaccines. We found that subcutaneous DNA injection with E7-CT (gp96) followed by electroporation generates the significant E7-specific IFN-γ immune responses as well as the best protective effects in vaccinated mice as compared to E7 or E7-NT (gp96) DNA vaccines. Therefore, our data indicate that subcutaneous administration of E7 DNA linked to CT (gp96) fragment followed by electroporation can significantly enhance the potency of DNA vaccines. Indeed, the structural domains of immuno-chaperones show the potential of generating effective immune responses against different clinical disorders such as cancer. Altogether, our results show that comparable regions of gp96 (N-/C-terminal fragments of gp96) may have qualitatively different immunological effects in vaccine design.
authors.affiliation: Molecular Immunology and Vaccine Research Lab., Pasteur Institute of Iran, Tehran, Iran.
authors.forename: Amin
authors.initials: A
authors.lastname: Daemi
authors.forename: Azam
authors.initials: A
authors.lastname: Bolhassani
authors.forename: Sima
authors.initials: S
authors.lastname: Rafati
authors.forename: Farnaz
authors.initials: F
authors.lastname: Zahedifard
authors.forename: Sahar
authors.initials: S
authors.lastname: Hosseinzadeh
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Doustdari
mesh_terms: D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000818:Animals; D019556:COS Cells; D019496:Cancer Vaccines / Q000008:administration & dosage* / Q000276:immunology; D002478:Cells, Cultured; D002522:Chlorocebus aethiops; D004279:DNA, Viral / Q000008:administration & dosage / Q000276:immunology; D018274:Electroporation; D005260:Female; D006023:Glycoproteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D049452:Green Fluorescent Proteins; D052162:Human papillomavirus 16 / Q000235:genetics / Q000276:immunology*; D006801:Humans; D007167:Immunotherapy; D007371:Interferon-gamma / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009369:Neoplasms / Q000517:prevention & control; D050725:Papillomavirus E7 Proteins / Q000008:administration & dosage / Q000235:genetics / Q000276:immunology; D030361:Papillomavirus Infections / Q000276:immunology / Q000517:prevention & control; D053918:Papillomavirus Vaccines / Q000276:immunology; D014611:Vaccination; D019444:Vaccines, DNA / Q000276:immunology*
chemical_list: D000276:Adjuvants, Immunologic; D019496:Cancer Vaccines; D004279:DNA, Viral; D006023:Glycoproteins; D050725:Papillomavirus E7 Proteins; D053918:Papillomavirus Vaccines; D019444:Vaccines, DNA; C059731:oncogene protein E7, Human papillomavirus type 16; D049452:Green Fluorescent Proteins; D007371:Interferon-gamma